SCHEMBL18384637

SCHEMBL18384637

COc1c2cc(C(C)=O)oc2c(OC)c2cccnc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 7/20 0.47
PDE4B Q07343 7/20 0.47
PDE4C Q08493 7/20 0.47
PDE4D Q08499 7/20 0.47
LMNA P02545 2/20 0.43
RECQL P46063 1/20 0.43
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
ATM Q13315 1/20 0.40
ALOX12 P18054 2/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
CCR6 P51684 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
KDM4E B2RXH2 3/20 0.39
LIPG Q9Y5X9 1/20 0.39
CYP3A4 P08684 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18384665 0.95 PDE4A (0.47) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL18384638 0.90 KDM4E (0.41) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL18384632 0.89 KDM4E (0.44) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL18384670 0.85 KDM4E (0.41) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL18384666 0.84 KDM4E (0.44) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL29488 0.82 LMNA (0.50) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL18384634 0.81 HTT (0.44) LMNAATMALDH1A1MAPTHTT
SCHEMBL18384636 0.78 CASP6 (0.37) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL21237006 0.77 CASP6 (0.39) LMNAATMALDH1A1MAPTHTT
SCHEMBL18473267 0.76 NSD2 (0.38) PDE4APDE4BPDE4CPDE4DLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10934309-B2 Tricyclic quinone derivative SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) 2021-03-02 US disclosed
US-20190241583-A1 NEW TRICYCLIC QUINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. 2019-08-08 US disclosed
EP-3127907-A1 NEW TRICYCLIC QUINONE DERIVATIVE Boston Biomedical, Inc. (US) 2017-02-08 EP disclosed
US-20170015677-A1 NEW TRICYCLIC QUINONE DERIVATIVE BOSTON BIOMEDICAL, INC. (US) 2017-01-19 US disclosed
US-20170015677-A1 NEW TRICYCLIC QUINONE DERIVATIVE BOSTON BIOMEDICAL, INC. (US) 2017-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190241583-A1 NEW TRICYCLIC QUINONE DERIVATIVE NQO1, SQOR, SULT1E1 PDE4A 3952/4885PDE4B 3741/4885PDE4C 3940/4885
US-20170015677-A1 NEW TRICYCLIC QUINONE DERIVATIVE NQO1, SQOR, SULT1E1 PDE4A 3952/4885PDE4B 3741/4885PDE4C 3940/4885
US-10934309-B2 Tricyclic quinone derivative NQO1, NQO2, SQOR PDE4A 4234/4885PDE4B 4106/4885PDE4C 4295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.